Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations

Experimental Dermatology

Volumn 24, Issue 2, 2015, Pages 155-157

  Cierlitza, Monika ^a   Chauvistré, Heike ^b   Bogeski, Ivan ^a   Zhang, Xin ^a   Hauschild, Axel ^c   Herlyn, Meenhard ^d   Schadendorf, Dirk ^b   Vogt, Thomas ^a   Roesch, Alexander ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d WISTAR INSTITUTE   (United States)

Author keywords

Melanoma; Mitochondria; Reactive oxygen species; Therapy resistance; Tumor heterogeneity

Indexed keywords

CHELATING AGENT; COPPER; ELESCLOMOL; REACTIVE OXYGEN METABOLITE; VEMURAFENIB; ANTINEOPLASTIC AGENT; HYDRAZINE DERIVATIVE; OXYGEN;

CANCER INHIBITION; CANCER RESISTANCE; CELL KILLING; CELL POPULATION; CYTOTOXICITY ASSAY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; MELANOMA; MELANOMA CELL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MONOTHERAPY; OXIDATIVE STRESS; TUMOR INVASION; CHEMISTRY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENOTYPE; METABOLISM; MULTIDRUG RESISTANCE; SKIN TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHELATING AGENTS; COPPER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENOTYPE; HUMANS; HYDRAZINES; MELANOMA; MITOCHONDRIA; OXIDATIVE STRESS; OXYGEN; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS;

EID: 84930410799     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12613     Document Type: Letter

References (19)

1. Hartsough E, Shao Y, Aplin A E. J Invest Dermatol 2014: 134: 319-325.
2. Shi H, Hugo W, Kong X et al. Cancer Discov 2014: 4: 80-93.
3. Roesch A, Fukunaga M, Schmidt E et al. Cell 2010: 141: 583-594.
4. Roesch A, Vultur A, Bogeski I et al. Cancer Cell 2013: 23: 811-825.
5. Yuan P, Ito K, Perez-Lorenzo R et al. Proc Natl Acad Sci USA 2013: 110: 18226-18231.
6. O'Day S J, Eggermont A M, Chiarion-Sileni V et al. J Clin Oncol 2013: 31: 1211-1218.
7. Blackman R K, Cheung-Ong K, Gebbia M et al. PLoS One 2012: 7: e29798.
8. Kirshner J R, He S, Balasubramanyam V et al. Mol Cancer Ther 2008: 7: 2319-2327.
9. Hasinoff B B, Yadav A A, Patel D et al. J Inorg Biochem 2014: 137: 22-30.
10. Barbi de Moura M, Vincent G, Fayewicz S L et al. PLoS One 2012: 7: e40690.
11. Brady D C, Crowe M S, Turski M L et al. Nature 2014: 509: 492-496.
12. Kluza J, Corazao-Rozas P, Touil Y et al. Cancer Res 2012: 72: 5035-5047.
13. Corazao-Rozas P, Guerreschi P, Jendoubi M et al. Oncotarget 2013: 4: 1986-1998.
14. Vander Heiden M G, Cantley L C, Thompson C B. Science 2009: 324: 1029-1033.
15. Berridge M V, Herst P M, Tan A S. Mitochondrion 2010: 10: 584-588.
16. O'Day S, Gonzalez R, Lawson D et al. J Clin Oncol 2009: 27: 5452-5458.
17. Koukourakis M I, Giatromanolaki A, Sivridis E et al. Br J Cancer 2003: 89: 877-885.
18. Semenza G L. Cancer Metastasis Rev 2000: 19: 59-65.
19. Ho J, de Moura M B, Lin Y et al. Mol Cancer 2012: 11: 76.